The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study
<i>Background</i>: Favipiravir has complex pharmacokinetics, and varied efficacy has been reported in treating COVID-19. Telehealth and telemonitoring are disruptive challenges used for COVID-19 care during pandemics. <i>Objective</i>: This study aimed to assess the outcome o...
Main Authors: | Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Kunsuda Cheirsilpa, Teerapat Ungtrakul, Wasanai Krisorakun, Chanisa Chotipanich, Nat Wimolsiri, Permpen Noitun, Netnapis Srirattana, Nithi Mahanonda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/59/6/1098 |
Similar Items
-
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)
by: Taweegrit Siripongboonsitti, et al.
Published: (2023-09-01) -
The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)
by: Taweegrit Siripongboonsitti, et al.
Published: (2023-12-01) -
A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)
by: Taweegrit Siripongboonsitti, et al.
Published: (2024-05-01) -
Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)
by: Taweegrit Siripongboonsitti, et al.
Published: (2023-09-01) -
Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline
by: Nanthida Phattraprayoon, et al.
Published: (2022-02-01)